These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 18491277)

  • 1. [Measuring plasma concentrations of antiretroviral drugs during HIV therapy].
    Langmann P
    Dtsch Med Wochenschr; 2008 May; 133(22):1205-6; author reply 1206-7. PubMed ID: 18491277
    [No Abstract]   [Full Text] [Related]  

  • 2. Simultaneous determination of 17 antiretroviral drugs in human plasma for quantitative analysis with liquid chromatography-tandem mass spectrometry.
    Jung BH; Rezk NL; Bridges AS; Corbett AH; Kashuba AD
    Biomed Chromatogr; 2007 Oct; 21(10):1095-104. PubMed ID: 17582235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Are plasma levels valid surrogates for cellular concentrations of antiretroviral drugs in HIV-infected patients?
    Colombo S; Telenti A; Buclin T; Furrer H; Lee BL; Biollaz J; Decosterd LA;
    Ther Drug Monit; 2006 Jun; 28(3):332-8. PubMed ID: 16778716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New antiretroviral agents and the complexity of treatment practices.
    Smith D
    J HIV Ther; 2008 Jun; 13(2):25-6. PubMed ID: 18953270
    [No Abstract]   [Full Text] [Related]  

  • 5. Evaluation of Elisa test for therapeutic monitoring of Nelfinavir in HIV-positive patients.
    Uglietti A; Genco F; Donadel E; Rinaldi S; Bastiani E; Maserati R; Meroni V
    New Microbiol; 2007 Jul; 30(3):318-20. PubMed ID: 17802918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can responses to antiretroviral therapy be improved by therapeutic drug monitoring?
    Haas DW
    Clin Infect Dis; 2006 Apr; 42(8):1197-9. PubMed ID: 16575742
    [No Abstract]   [Full Text] [Related]  

  • 7. Standard methods to measure HIV drug concentrations.
    Luber AD; Merry C
    Lancet; 2001 Sep; 358(9285):930. PubMed ID: 11575381
    [No Abstract]   [Full Text] [Related]  

  • 8. Virological suppression achieved with suboptimal adherence levels among South African children receiving boosted protease inhibitor-based antiretroviral therapy.
    Müller AD; Myer L; Jaspan H
    Clin Infect Dis; 2009 Jan; 48(1):e3-5. PubMed ID: 19025495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protease inhibitor plasma concentrations in HIV antiretroviral therapy.
    Justesen US
    Dan Med Bull; 2008 Nov; 55(4):165-85. PubMed ID: 19232158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on antiretroviral therapy.
    Riordan A; Bugembe T
    Arch Dis Child; 2009 Jan; 94(1):70-4. PubMed ID: 18838416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Determination of serum levels of antiretroviral drugs].
    Kurowski M
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():62-4. PubMed ID: 15373053
    [No Abstract]   [Full Text] [Related]  

  • 12. Cardiovascular risks of antiretroviral therapy.
    Stein JH
    N Engl J Med; 2007 Apr; 356(17):1773-5. PubMed ID: 17460232
    [No Abstract]   [Full Text] [Related]  

  • 13. Warfarin-antiretroviral interactions.
    Liedtke MD; Rathbun RC
    Ann Pharmacother; 2009 Feb; 43(2):322-8. PubMed ID: 19196837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Antiretroviral therapy of HIV infection. German-Austrian guidelines (position in September 2008)].
    ;
    Dtsch Med Wochenschr; 2009 Jan; 134 Suppl 1():S4-15. PubMed ID: 19172554
    [No Abstract]   [Full Text] [Related]  

  • 15. A liquid chromatography-tandem mass spectrometry assay for quantification of nevirapine, indinavir, atazanavir, amprenavir, saquinavir, ritonavir, lopinavir, efavirenz, tipranavir, darunavir and maraviroc in the plasma of patients infected with HIV.
    Martin J; Deslandes G; Dailly E; Renaud C; Reliquet V; Raffi F; Jolliet P
    J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Oct; 877(27):3072-82. PubMed ID: 19699694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic monitoring of HIV-1 protease inhibitors in the antiretroviral therapy.
    Pawiński T; Pulik P; Gralak B; Horban A
    Acta Pol Pharm; 2008; 65(1):93-100. PubMed ID: 18536180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of PI and NNRTI HAART-based therapy on oral lesions of Brazilian HIV-infected patients.
    Ortega KL; Vale DA; Magalhães MH
    J Oral Pathol Med; 2009 Jul; 38(6):489-94. PubMed ID: 19453845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Metabolic side effects of antiretroviral therapy].
    van der Valk M; Reiss P
    Ned Tijdschr Geneeskd; 2008 May; 152(22):1260-4. PubMed ID: 18590059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Boosted protease inhibitor-based or nonnucleoside reverse transcriptase-based HAART: is there a best choice for antiretroviral-naive HIV-1 infected patients?
    Cuzin L; Allavena C; Morlat P; Dellamonica P
    AIDS Rev; 2008; 10(4):205-11. PubMed ID: 19092976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [HIV-1 protease inhibitors: cell metabolism and drug resistance (review)].
    Bobkova MR
    Ter Arkh; 2008; 80(10):77-80. PubMed ID: 19105421
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.